Our study demonstrates that a GARP targeted theranostic probe may be an innovative strategy to detect and quantify GARP expression in vivo in our TNBC model in order to perform tumour phenotyping, determine aggressiveness and predict escape or resistance to treatments. The gene discussed is LRRC32; the disease is neoplasm.